All In Biotech

Drug Trial Radar · NCT07675057

Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Expanded Access for Vepugratinib in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jun 30, 2026

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Conditions

  • Urinary Bladder Neoplasms
  • Neoplasm Metastasis
  • Carcinoma, Transitional Cell

Interventions

  • VepugratinibDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.